Payment overview · 2025
General Payments
$186.97
10 reported records · 8 companies
Healthcare provider profile · identity verified
Gerard H Murphy, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CHILHOWIE, VA · NPI 1104995414
Verified facts
What the public records show
CMS Open Payments records show Gerard H Murphy, M.D. received $186.97 in general payments during 2025 across 10 reported records.
Lilly USA, LLC accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 253 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.75 | 21.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.65 | 17.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.09 | 12.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.95 | 11.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.45 | 10.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.30 | 9.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.82 | 9.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.96 | 7.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $186.97 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $40.75 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.09 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.95 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.45 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
64 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
253 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 590 | 123 |
| Losartan Potassium | Losartan Potassium | 480 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 427 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 419 | 87 |
| Gabapentin | Gabapentin | 398 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 374 | 75 |
| Omeprazole | Omeprazole | 370 | 74 |
| Potassium Chloride | Potassium Chloride | 366 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 333 | 70 |
| Lisinopril | Lisinopril | 311 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 303 | 67 |
| Furosemide | Furosemide | 268 | 50 |
| Metformin Hcl | Metformin Hcl | 267 | 47 |
| Sertraline Hcl | Sertraline Hcl | 263 | 48 |
| Alprazolam | Alprazolam | 258 | 37 |
| Eliquis | Apixaban | 253 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 252 | 52 |
| Metformin Hcl Er | Metformin Hcl | 247 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 236 | 42 |
| Meloxicam | Meloxicam | 212 | 40 |
| Montelukast Sodium | Montelukast Sodium | 198 | 33 |
| Simvastatin | Simvastatin | 173 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 168 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 166 | 30 |
| Allopurinol | Allopurinol | 155 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 31 |
| Bupropion Xl | Bupropion Hcl | 146 | 24 |
| Lorazepam | Lorazepam | 141 | 25 |
| Glipizide Er | Glipizide | 138 | 25 |
| Famotidine | Famotidine | 136 | 28 |
| Clonazepam | Clonazepam | 133 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 129 | 22 |
| Carvedilol | Carvedilol | 128 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 126 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 123 | 18 |
| Trazodone Hcl | Trazodone Hcl | 116 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 99 | 32 |
| Ezetimibe | Ezetimibe | 96 | 22 |
| Sucralfate | Sucralfate | 95 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 24 |
| Warfarin Sodium | Warfarin Sodium | 94 | 14 |
| Atenolol | Atenolol | 93 | 26 |
| Ozempic | Semaglutide | 92 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 92 | 15 |
| Propranolol Hcl | Propranolol Hcl | 89 | 18 |
| Valsartan | Valsartan | 86 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 82 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 18 |
| Chlorthalidone | Chlorthalidone | 78 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 78 | 19 |
| Januvia | Sitagliptin Phosphate | 73 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | 12 |
| Nystatin | Nystatin | 69 | 13 |
| Buspirone Hcl | Buspirone Hcl | 68 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 68 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 15 |
| Glimepiride | Glimepiride | 64 | 12 |
| Synthroid | Levothyroxine Sodium | 64 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 63 | 18 |
| Prednisone | Prednisone | 63 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 11 |
| Donepezil Hcl | Donepezil Hcl | 54 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 14 |
| Meclizine Hcl | Meclizine Hcl | 53 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 52 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | suppressed |
| Mounjaro | Tirzepatide | 49 | suppressed |
| Pregabalin | Pregabalin | 49 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 49 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 45 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 43 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | suppressed |
| Trulicity | Dulaglutide | 42 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 41 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | suppressed |
| Topiramate | Topiramate | 40 | suppressed |
| Fluconazole | Fluconazole | 39 | 18 |
| Methotrexate | Methotrexate Sodium | 39 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | suppressed |
| Jardiance | Empagliflozin | 37 | suppressed |
| Spironolactone | Spironolactone | 37 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Ibuprofen | Ibuprofen | 35 | 11 |
| Temazepam | Temazepam | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | 11 |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Brilinta | Ticagrelor | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Carbamazepine | Carbamazepine | 31 | suppressed |
| Lactulose | Lactulose | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Torsemide | Torsemide | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Primidone | Primidone | 27 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 16 |
| Celecoxib | Celecoxib | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 23 | 23 |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 11 |
| Rybelsus | Semaglutide | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Ibu | Ibuprofen | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 13 |
| Nyamyc | Nystatin | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 19 | suppressed |
| Jantoven | Warfarin Sodium | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 18 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 14 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Glipizide Xl | Glipizide | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Enulose | Lactulose | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Hydroxyurea | Hydroxyurea | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Neurontin | Gabapentin | 13 | suppressed |
| Otezla | Apremilast | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Zileuton Er | Zileuton | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $186.97 · 10 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, BREZTRI, Cologuard Collection Kit, FREESTYLE LIBRE 3, MOUNJARO, PREVNAR 20, VIBERZI, Wegovy, XIFAXAN, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error